To test the proposal that BRCT domains serve to mediate protein-protein interactions [1,2,6], we have disrupted a BRCT domain. We generated targeted deletions and point mutations within the BRCT II domain of XRCC1 to identify the motifs that are required and sufficient for the interaction of XRCC1 with DNA ligase 7, 8] . Wildtype and mutant histidine (His)-tagged human XRCC1 polypeptides were purified from Escherichia coli and compared for their ability to interact with human DNA ligase III-α by 'pull-down' assays and 'far-western' blotting ( Figure 1) . The interaction of DNA ligase III-α with a truncated XRCC1 polypeptide, XRCC1 1-592 , was reduced fivefold compared with full-length XRCC1, and the interaction of DNA ligase III-α with two other truncated XRCC1 molecules, XRCC1 1-573 and XRCC1 ∆575-589 , was reduced more than 30-fold (Figure 1b) . These results indicate that the region of BRCT II downstream of amino acid 573 is important for interaction with DNA ligase III-α, and that the region between residues 573 and 592 is critical for this interaction. Residues 573-592 span the C-block motif of BRCT II, which is one of the five conserved blocks (Figure 1 ) [1, 2] . The importance of the C-block for interaction with DNA ligase III-α was confirmed by the activity of the XRCC1 VI584/585DD polypeptide, in which two of the non-charged residues characteristic of C-block motifs were substituted with aspartate. This mutant had less than 3% of the DNA ligase III-α binding activity exhibited by wild-type XRCC1 (Figure 1b) . In contrast, substitution of the D-block residue Trp 611 with aspartate (XRCC1 W611D ) did not significantly disrupt the interaction with DNA ligase III-α (Figure 1b) . It is intriguing that Trp 611 is dispensable, as it is one of the two most conserved amino acids in BRCT domains and is a defining feature of the D-block motif, which is itself the most conserved motif in BRCT domains [1, 2] .
Results and discussion
To test the proposal that BRCT domains serve to mediate protein-protein interactions [1, 2, 6] , we have disrupted a BRCT domain. We generated targeted deletions and point mutations within the BRCT II domain of XRCC1 to identify the motifs that are required and sufficient for the interaction of XRCC1 with DNA ligase III-α [4, 7, 8] . Wildtype and mutant histidine (His)-tagged human XRCC1 polypeptides were purified from Escherichia coli and compared for their ability to interact with human DNA ligase III-α by 'pull-down' assays and 'far-western' blotting ( Figure 1 ). The interaction of DNA ligase III-α with a truncated XRCC1 polypeptide, XRCC1 , was reduced fivefold compared with full-length XRCC1, and the interaction of DNA ligase III-α with two other truncated XRCC1 molecules, XRCC1 and XRCC1 ∆575-589 , was reduced more than 30-fold (Figure 1b) . These results indicate that the region of BRCT II downstream of amino acid 573 is important for interaction with DNA ligase III-α, and that the region between residues 573 and 592 is critical for this interaction. Residues 573-592 span the C-block motif of BRCT II, which is one of the five conserved blocks ( Figure 1 ) [1, 2] . The importance of the C-block for interaction with DNA ligase III-α was confirmed by the activity of the XRCC1 VI584/585DD polypeptide, in which two of the non-charged residues characteristic of C-block motifs were substituted with aspartate. This mutant had less than 3% of the DNA ligase III-α binding activity exhibited by wild-type XRCC1 (Figure 1b) . In contrast, substitution of the D-block residue Trp 611 with aspartate (XRCC1 W611D ) did not significantly disrupt the interaction with DNA ligase III-α (Figure 1b) . It is intriguing that Trp 611 is dispensable, as it is one of the two most conserved amino acids in BRCT domains and is a defining feature of the D-block motif, which is itself the most conserved motif in BRCT domains [1, 2] .
These results indicate that the C-block motif of BRCT II is critical for the interaction of XRCC1 with DNA ligase III-α. To examine whether the C-block is sufficient for interaction with DNA ligase III-α, a peptide comprising the 20 amino acids that span this region was tested for its ability to confer the property of binding the DNA ligase upon an unrelated polypeptide. An oligonucleotide duplex encoding residues 573-592 of XRCC1 was cloned into the E. coli expression vector pMAL-cR1 downstream of an open reading frame (ORF) encoding the bacterial maltose binding protein (MBP). The resulting construct encoded a tripartite polypeptide comprising MBP, XRCC1 573-592 and the α-fragment of β-galactosidase (Figure 2a ). This polypeptide, denoted MBP-X 573-592 , was compared with one expressed from the pMAL-cR1 vector (MBP-β-galactosidase α, denoted MBP, Figure 2a) for the ability to interact with Histagged DNA ligase III-α immobilised on agarose beads in a pull-down assay. His-DNA ligase III-α bound to agarose was incubated with either MBP or MBP-X 573-592 and the beads recovered by centrifugation. After extensive washing, His-DNA ligase III-α and any associated MBP fusion proteins were fractionated by SDS-PAGE and detected by immunoblotting (with anti-MBP antisera) or staining with Coomassie blue. These experiments revealed that 25-fold more MBP-X 573-592 than MBP was bound by His-DNA ligase III-α (Figure 2b C-block region is inserted into MBP is either not required or is fulfilled by the β-galactosidase fragment.
To examine the specificity of the interaction between His-DNA ligase III-α and MBP-X 573-592 , we determined whether MBP-X 573-592 bound His-DNA ligase III-α within the same region bound by full-length XRCC1. We used a preparation of recombinant His-DNA ligase III-α that contained truncated His-DNA ligase III-α polypeptides lacking the normal carboxyl terminus, in addition to containing the full-length protein (see Figure 2d legend). We reasoned that because full-length XRCC1 interacts with the carboxyl terminus of DNA ligase III-α, MBP-X 573-592 should bind only full-length DNA ligase III-α if it also targets the carboxyl terminus. Indeed, full-length DNA ligase III-α was efficiently separated from the truncated polypeptides by MBP-X 573-592 bound to agarose beads in a pull-down assay (Figure 2d ).
The XRCC1 mutant CHO cell lines EM9 and EM-C11 possess reduced levels (4-6-fold) of DNA ligase III-α protein and cannot efficiently rejoin DNA single-strand breaks arising from ionising radiation and certain alkylating agents [5, [7] [8] [9] [10] . Moreover, EM-C11 cell extract cannot efficiently ligate DNA single-strand breaks during DNA baseexcision repair in vitro, a deficiency that is complemented by the addition of recombinant DNA ligase [5] . To examine whether the C-block of BRCT II is required to maintain normal cellular levels of DNA ligase III-α and consequently required for normal DNA repair, we compared XRCC1 and XRCC1 ∆575-589 proteins for their ability to increase the level of DNA ligase III-α in EM9 transfectants. Immunoblots probed with anti-DNA ligase III polyclonal antibody revealed that whereas full-length XRCC1 did increase DNA ligase III-α to normal levels, XRCC1 ∆575-589 failed to elevate the level of the ligase above levels present in EM9 cells transfected with 'empty' vector ( Figure 3 and data not Brief Communication 879 shown). Thus, the C-block motif of BRCT II is required to maintain normal cellular levels of DNA ligase III-α.
The results described here demonstrate that the BRCT II domain of XRCC1 facilitates the physical interaction of this essential DNA repair protein with DNA ligase III-α and indicate that this interaction is required to maintain normal cellular levels of the ligase. These data thus demonstrate that the BRCT II domain facilitates a biologically important protein-protein interaction, and support the hypothesis that the role of BRCT domains is to mediate such interactions [1, 2, 6] . It seems likely, however, that BRCT II also fulfils another role, as it is unlikely that such a large and complex structure is required solely for interaction with DNA ligase III-α. Consistent with this, the highly conserved tryptophan that in part defines the D-block of BRCT domains was dispensable for this interaction. Thus, it is likely that at least some amino acids located carboxy-terminal to the C-block in BRCT II fulfil another role, which is conserved in other BRCT domains. One possibility is that they have a role in signal transduction. For example, each BRCT domain could mediate an interaction that is unique to that domain (for example, via the weakly conserved C-block motif) in combination with an interaction that is common to all domains (for example, via the highly conserved D-block motif). In this scenario, BRCT domains could behave as adaptor molecules capable of linking different cellular processes (such as DNA repair and cell cycle control) to a common or related signal transduction pathway.
Materials and methods
Far-western blotting was conducted as described [8, 11] . Briefly, recombinant human XRCC1 was phosphorylated with casein kinase II (Boehringer Mannheim) in the presence of γ-[ 32 P]ATP. Labelled XRCC1 probes (1 µg at 50 ng/ml) were incubated with nitrocellulose blots containing renatured human DNA ligase III-α that had previously been fractionated by SDS-PAGE. XRCC1-DNA ligase III-α complexes were detected by autoradiography. Pull-down assays were conducted as described [4, 8, 11] . Briefly, His-DNA ligase III-α (1 nM) or His-XRCC1 (1 nM) bound to nickel-NTA agarose beads, or MBP-X 573-592 (1 nM) bound to agarose beads, were incubated with purified MBP fusion proteins (1 nM), DNA ligase III-α (~1 nM) in E. coli extract, or a heterogeneous mixture of purified His-DNA ligase III-α polypeptides (1 nM), respectively. After 20-30 min, agarose beads were recovered by low-speed centrifugation, washed extensively, and bead-bound proteins eluted with 200 mM imidazole for nickel-NTA agarose complexes, or 1 M NaCl for agarose-MBP-X 573-592 complexes. Following SDS-PAGE, gels were stained with Coomassie blue to detect total protein or with appropriate antibodies (singly or in combination) to detect XRCC1 and MBP fusion proteins. In control experiments, the XRCC1 mutations described did not affect the interaction of XRCC1 with DNA polymerase-β, a polypeptide that interacts with XRCC1 outside the BRCT II domain ( [12, 13] and data not shown). 
